• Tacrine Hydrochloride Hydrate: Assay Workflows

  2026-09-23

  Use Tacrine hydrochloride hydrate to benchmark cholinesterase inhibition, then extend the workflow to cell-based cholinergic and neuroprotection studies. Practical concentration planning, controls, and metabolism-aware assay design help distinguish target engagement from downstream effects.

• ERAD-Hijacking Chimeras for TM Protein Degradation

  2026-09-23

  Song and colleagues establish ERAD-engaging chimeras (ERADECs), a small-molecule targeted protein degradation platform designed to remove transmembrane proteins through the endoplasmic reticulum-associated degradation pathway. By identifying desonide as a SYVN1-binding warhead, the study achieves highly effective PD-L1 degradation and demonstrates broader applicability to mutant HTT protein.

• Crystal Violet Staining Solution: Assay Logic

  2026-09-22

  Crystal Violet Staining Solution is a practical nuclear staining dye for cell-based endpoint analysis. This guide explains how to interpret its signal across proliferation, migration, invasion, and colony assays while separating validated evidence from workflow recommendations.

• GRK Control of Biased M1 Receptor Signaling

  2026-09-22

  A 2025 study used quantitative BRET assays to define how GRK subtype behavior shapes M1 muscarinic receptor coupling to G proteins and β-arrestin 2. Its analysis of BQCA shows that allosteric modulation can alter acetylcholine sensitivity across both signaling branches, while GRK2/3 versus GRK5/6 engagement tracks with signaling bias.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-09-21

  Masitinib (AB1010) provides a DMSO-compatible approach for studying KIT, PDGFRα, and PDGFRβ inhibition in cancer, mast cell, and inflammatory disease models. It is appropriate for controlled biochemical and cell-based assays, but not for workflows requiring aqueous or ethanol solubility, broad kinase inhibition, or direct clinical treatment guidance.

• P101 Probiotic Protection in Alcoholic Steatosis

  2026-09-21

  A 2025 mouse study found that Lactiplantibacillus plantarum P101 reduced alcohol-associated hepatic lipid accumulation while activating AMPK. By combining pharmacological inhibition with gut microbiota and serum metabolomics analyses, the study linked probiotic protection to AMPK signaling while identifying microbial and metabolic candidates for further validation.

• Machine Learning for Senolytic Discovery

  2026-09-20

  The reference study demonstrates that cost-effective machine learning can identify senolytic compounds from small, heterogeneous collections of published screening data. Its computational prioritization and experimental validation identified ginkgetin, periplocin, and oleandrin, illustrating how data-driven screening can reduce early drug-discovery costs while retaining biological relevance.

• HHV-7 DNA in Ocular Toxoplasmosis: Study Insights

  2026-09-19

  Miyase et al. reported the first vitreous-fluid detection of HHV-7 DNA in a patient with recurrent ocular toxoplasmosis, alongside Toxoplasma gondii DNA. The case highlights how multiplex PCR and therapeutic response can identify clinically relevant coinfection hypotheses, while also showing why molecular detection alone cannot establish causality.

• Otilonium Bromide for Cholinergic Assays

  2026-09-18

  Use Otilonium Bromide as a practical antimuscarinic agent for separating receptor-driven effects from nonspecific toxicity in cell, tissue, and gastrointestinal motility workflows. This guide combines concentration planning, vehicle controls, functional readouts, and a carefully bounded lesson from structure-based inhibitor screening.

• Cordycepin–PDT Triggers Pyroptosis in Breast Cancer

  2026-09-18

  A 2026 pre-proof study reports that cordycepin substantially strengthens photodynamic therapy against breast cancer cells by promoting ROS accumulation and NLRP3/caspase-1/GSDMD-dependent pyroptosis. Its integrated viability, redox, mitochondrial, inflammatory, and inhibitor experiments provide a mechanistic framework for evaluating combination PDT strategies, while remaining limited to in vitro evidence.

• RESTRICT-seq Maps Epigenetic Dependencies in SCC

  2026-09-17

  The RESTRICT-seq preprint introduces a time-gated CRISPR screening strategy for identifying epigenetic dependencies associated with squamous cell carcinoma resistance. Its main implication is methodological: resistance biology may be missed when genetic perturbations and phenotypic measurements are treated as static events rather than time-dependent processes.

• Atrial Natriuretic Peptide: Assay Design Guide

  2026-09-17

  A practical, mechanistic guide to Atrial Natriuretic Peptide research that distinguishes the rat ANP 1-11 fragment from native hormone biology. Learn how to design better cardiovascular assays and interpret cross-domain evidence without overextending adiponectin findings.

• Nelfinavir Mesylate in HIV and Ferroptosis Research

  2026-09-16

  Nelfinavir Mesylate combines a validated HIV-1 protease mechanism with an emerging use as a ferroptosis-sensitization tool through the DDI2-NFE2L1-proteasome axis. This article presents practical assay workflows, dosing logic, controls, and troubleshooting strategies for antiviral and cellular-stress research.

• Acetylcholine Chloride in Gut-Brain Research

  2026-09-15

  Acetylcholine Chloride provides a defined chemical stimulus for separating receptor-level cholinergic effects from microbiota-driven gut-brain signaling. This workflow shows how to use it as a reproducible positive control alongside vagal recordings, intestinal tissue assays, and seizure-model studies.

• D-N-Acetylgalactosamine: Practical Lab Guide

  2026-09-15

  D-N-Acetylgalactosamine (SKU B7904) provides a defined carbohydrate metabolite for glycoprotein composition, brain heteropolysaccharides analysis, and glycosylation pathway workflows. It is suitable for aqueous or DMSO-based preparation, but not for ethanol dissolution or long-term storage of working solutions.

7961 records 1/531 page Next 12345 下5页 Last page